Dr. Reddy’s Laboratories Announces Launch of ‘Obeda'

Hyderabad, India, May 24, 2026: Dr. Reddy’s Laboratories Ltd a global pharmaceutical company, today announced the launch of its oral semaglutide biosimilar, indicated for type 2 diabetes mellitus. Dr. Reddy’s oral semaglutide is available in tablet form under the brand name Obeda® in India. This launch follows Dr. Reddy’s recent generic Semaglutide injection launches in India and Canada, further establishing the company’s position as a full‑stack player in GLP‑1 therapies.

As per the ICMR‑INDIAB study, India represents one of the world’s largest diabetes burdens with over 101 million adults living with the condition and a prevalence of 11.4%. Alarmingly, nearly 136 million individuals are prediabetic, and close to 40% of adults have abdominal obesity, placing them at high risk of progression. Despite multiple treatment options, uncontrolled type 2 diabetes remains a significant challenge. 

Dr. Reddy’s Obeda® (semaglutide tablets) is formulated using recombinant DNA (rDNA) origin of semaglutide active pharmaceutical ingredient (API). Dr. Reddy’s obtained approval for its oral semaglutide biosimilar from the CDSCO following a review of a Phase III clinical study enrolling 288 participants with type 2 diabetes mellitus conducted in India, which demonstrated non-inferior efficacy and a safety profile comparable to the innovator oral drug. Dr. Reddy’s Obeda® (semaglutide tablets) is available in 3 mg, 7 mg and 14 mg strengths and recommended for once-daily oral use. It is priced at Rs. 99, Rs. 135, and Rs. 225 per tablet for the 3 mg, 7 mg, and 14 mg doses, respectively.

M.V. Ramana, Chief Executive Officer, Global Generics, Dr. Reddy’s, said: “The launch of our oral semaglutide for patients with diabetes marks an important step in our journey to broaden access to advanced diabetes care. We recognize that every patient’s journey with diabetes is different, and treatment choices must reflect that diversity.